Key Takeaways Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe.Chinese firm 3SBio is developing a drug that is in trials to treat several forms of cancer,

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more on the deal and its PFE implications.

Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug undergoing trials for treatment of certain types of cancer and tumours,